 | | Vol. 13.41 – 18 October, 2022 |
| |
|
|
| BefA disseminated systemically by multiple anatomic routes to act directly on pancreatic islets. A BefA mutant impaired in membrane disruption failed to expand β cells, whereas the pore-forming host defense protein, Reg3, stimulated β cell proliferation.
[Cell Metabolism] |
|  |
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
| |
|
|
| The authors isolated pancreatic islets from the control and type 2 diabetes mice for scRNA-seq and retrieved multiple datasets from the open databases. The complete islets cell landscape and robust marker genes and transcription factors of each endocrine cell type were identified.
[iScience] |
|
|
|
| | Scientists reported that RAS-ON (RASON) was a positive regulator of oncogenic RAS signaling, and was aberrantly overexpressed in PDAC patients, promoting proliferation of human PDAC cell lines in vitro and tumor growth in vivo.
[Cell Research] |
|
|
|
| The effects of Corynoxine were evaluated on two pancreatic cancer cell lines, Patu-8988 and Panc-1, using cell viability analysis, EdU staining, TUNEL assay, colony formation assay, and flow cytometry.
[British Journal of Cancer] |
|
|
|
| Investigators showed that cisplatin-resistant PDAC regrew primary cilia. Additionally, genetic or pharmacological disruption of primary cilia sensitized PDAC to cisplatin treatment.
[Journal of Cellular Physiology] |
|
|
|
| 15 hub genes were identified, among which inducible T cell co‑stimulator was indicated to serve a role in the most pivotal immunity pathways. pSS was markedly associated with inflammatory pathways.
[Molecular Medicine Reports] |
|  |
|
|
|
| Scientists examine the association between the use of antibiotics and the onset and development of both type 1 and type 2 diabetes, inflammatory bowel disease, including ulcerative colitis and Crohn’s disease, as well as coeliac disease and eosinophilic oesophagitis.
[Nature Reviews Gastroenterology & Hepatology] |
|
|
|
| The author discusses the current understanding of the mechanisms by which hypoglycaemia is detected and the consequences of recurrent exposure to hypoglycaemia.
[Diabetic Medicine] |
|
|
|
|
| The Phase I study will evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of PT217 in subjects with advanced or refractory cancers. Patients with several tumor types will be eligible for screening, including gastroenteropancreatic neuroendocrine tumors.
[Phanes Therapeutics Inc] |
|
|
|
|
| November 14 – 17, 2022
Portland, Oregon, United States |
|
|
|
|
|
| | University of Oxford – Oxford, United Kingdom |
|
|
|
| | University of Southern Denmark – Odense, Denmark |
|
|
|
| | University of Colorado Denver – Aurora, Colorado, United States |
|
|
|
| | University of Illinois Chicago – Chicago, Illinois, United States |
|
|
|
| | University of Gothenburg – Gothenburg, Sweden |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
